Compare CHOW & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHOW | INTS |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3M | 13.7M |
| IPO Year | 2024 | 2021 |
| Metric | CHOW | INTS |
|---|---|---|
| Price | $0.48 | $4.10 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $38.00 |
| AVG Volume (30 Days) | ★ 12.6M | 30.3K |
| Earning Date | 06-17-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.80 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.27 | $0.22 |
| 52 Week High | $12.05 | $8.06 |
| Indicator | CHOW | INTS |
|---|---|---|
| Relative Strength Index (RSI) | 54.06 | 41.78 |
| Support Level | $0.36 | $3.95 |
| Resistance Level | $0.59 | $5.09 |
| Average True Range (ATR) | 0.09 | 0.32 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 21.54 | 8.94 |
ChowChow Cloud International Holdings Ltd provides one-stop cloud solutions that support companies across the IT industry value chain throughout their entire cloud transformation journey, from consulting, deployment, and migration to cloud environment building and management. Its business comprises (i) digital transformation consulting services consisting of cloud suitability assessment, (ii) professional IT services comprising capabilities designed to facilitate seamless cloud integration and digital transformation, (iii) AI-powered proactive cloud managed services covering all aspects of day-to-day cloud maintenance and support, and (iv) IT infrastructure solutions covering on-premise private cloud setups and public cloud integrations, including infrastructure applications.
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.